Market News / Story
FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis…
GlobeNewswire ·
GlobeNewswire reports: Potentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults annually and contributes to nearly one in three in-hospital deaths DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation , a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Food and Drug…